ArticleBlood purification2026
Could Serum CA125 Aid the Clinical Assessment of Volume Status of End-Stage Kidney Disease Patients Treated by Peritoneal Dialysis Patients?
Article in Blood purification, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionVolume overload is a major cause of technique failure, morbidity and mortality for peritoneal dialysis patients (PD). Biomarkers could potentially aid the clinical assessment of patients. Recently, Cancer antigen 125 (CA125) has been reported to predict volume status and outcomes in heart failure patients. As such we wished to evaluate CA125 in PD patients.
methodsSerum CA125 was measured in patients attending for peritoneal membrane assessment, along with bioimpedance, N-terminal probrain natriuretic peptide (NT-proBNP), who had echocardiography measurements.
resultResults from 571 PD patients, mean age 53.8 ± 10.5 years 62.4% male, 44.0% diabetic, median PD treatment 2 (2-3) months were reviewed. Serum CA125 was higher in women vs. men (25 (16-38) vs. 17 (11-29) IU/L, p < 0.05, serum CA125 was positively associated with peritoneal solute transfer rates (PSTRs) (r = 0.35), extracellular water/intracellular water (ECW/ICW) (r = 0.28), NT-proBNP (r = 0.22), and negatively with left ventricular ejection fraction (r = -0.15), all p < 0.001. Unlike other biomarkers, there was no association with residual kidney function (r = -0.05 p = 0.21). On multivariable analysis, log CA125 was associated with female gender (standardised beta [Stβ] -0.224, PSTR Stβ 0.227, comorbidity score Stβ 0.16, serum sodium Stβ -0.146 all p < 0.001, left ventricular ejection fraction Stβ -0.102, p = 0.01, and ECW/ICW ratio Stβ 0.009, p = 0.038).
conclusionAlthough serum CA125 values were higher in female patients, patients with higher CA125 levels had increased markers of volume overload or reduced left ventricular ejection fraction, in keeping with previous cardiology studies, and so serial measurements may potentially aid the clinical assessment of volume status in PD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.